Chemours (CC) reported $1.36 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 0.2%. EPS of $0.11 for the same period compares to $0.31 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.36 billion, representing a surprise of -0.06%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.10.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Other Segment: $13 million compared to the $8.16 million average estimate based on three analysts.
- Revenues- Titanium Technologies: $632 million compared to the $618.85 million average estimate based on three analysts.
- Revenues- Advanced Performance Materials: $324 million compared to the $332.61 million average estimate based on three analysts.
- Revenues- Thermal & Specialized Solutions: $390 million versus $400.22 million estimated by three analysts on average.
- Adjusted EBITDA- Titanium Technologies: $77 million versus the three-analyst average estimate of $69.61 million.
- Adjusted EBITDA- Advanced Performance Materials: $48 million versus $39.15 million estimated by three analysts on average.
- Adjusted EBITDA- Thermal & Specialized Solutions: $123 million versus $111.52 million estimated by three analysts on average.
Shares of Chemours have returned -13.3% over the past month versus the Zacks S&P 500 composite's +4.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>The Chemours Company (CC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
